HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joseph J Buggy Selected Research

B-Cell Antigen Receptors (B Cell Antigen Receptors)

1/2013Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
4/2012Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.
3/2012The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
7/2010The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joseph J Buggy Research Topics

Disease

17Neoplasms (Cancer)
10/2018 - 07/2004
12B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2015 - 06/2011
5Lymphocytosis
02/2015 - 02/2012
4Non-Hodgkin Lymphoma (Lymphosarcoma)
08/2013 - 07/2010
3Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/2013 - 08/2013
3Lymphoma (Lymphomas)
06/2012 - 07/2011
2Bone Resorption
03/2014 - 08/2012
2Autoimmune Diseases (Autoimmune Disease)
11/2012 - 07/2010
2Inflammation (Inflammations)
11/2011 - 07/2011
2Experimental Arthritis
07/2011 - 07/2010
1Osteoporosis
03/2014
1Bone Diseases (Bone Disease)
03/2014
1Communicable Diseases (Infectious Diseases)
10/2013
1Parasitic Diseases (Parasitic Disease)
10/2013
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2013
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/2012
1Multiple Myeloma
08/2012
1Osteolysis
08/2012
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
06/2012
1Lymphadenopathy
03/2012
1Disease Progression
02/2012
1Insulinoma
11/2011
1Arthritis (Polyarthritis)
07/2011
1Anaphylaxis (Anaphylactic Shock)
07/2011
1Kidney Diseases (Kidney Disease)
07/2010
1Chromosome Breakage
12/2007
1Colorectal Neoplasms (Colorectal Cancer)
07/2006
1Body Weight (Weight, Body)
05/2006

Drug/Important Bio-Agent (IBA)

18ibrutinibIBA
02/2015 - 07/2010
14Agammaglobulinaemia Tyrosine KinaseIBA
06/2014 - 07/2010
4B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA
01/2013 - 07/2010
2Phosphotransferases (Kinase)IBA
01/2013 - 02/2012
2AutoantibodiesIBA
11/2012 - 07/2010
2Histone Deacetylase InhibitorsIBA
12/2007 - 07/2004
2Histone Deacetylases (Histone Deacetylase)IBA
12/2007 - 05/2006
2Hydroxamic Acids (Hydroxamic Acid)IBA
12/2007 - 05/2006
2abexinostatIBA
12/2007 - 05/2006
2TubulinIBA
07/2006 - 05/2006
2Histones (Histone)IBA
07/2006 - 05/2006
1Interleukin-2 (IL2)IBA
10/2018
1ciforadenantIBA
10/2018
1Adenosine (Adenocard)FDA LinkGeneric
10/2018
1AntigensIBA
02/2014
1Nuclear Antigens (Extractable Nuclear Antigens)IBA
11/2012
1Macrophage Colony-Stimulating FactorIBA
08/2012
1InterferonsIBA
06/2012
1Lenalidomide (CC 5013)FDA Link
06/2012
1Pharmaceutical PreparationsIBA
03/2012
1Fibronectins (Fibronectin)IBA
03/2012
1IntegrinsIBA
03/2012
1ChemokinesIBA
03/2012
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
03/2012
1Transcription Factors (Transcription Factor)IBA
11/2011
1Cromolyn Sodium (Cromoglicic Acid)FDA LinkGeneric
11/2011
1Antigen-Antibody Complex (Immune Complex)IBA
07/2011
1CollagenIBA
07/2011
1Protein Isoforms (Isoforms)IBA
08/2009
1Bevacizumab (Avastin)FDA Link
07/2006
1CRA 026440IBA
07/2006

Therapy/Procedure

4Therapeutics
01/2014 - 11/2011
1Aftercare (After-Treatment)
02/2015
1Ligation
02/2014